Board of Directors
Board of Directors
Chairman of AnaptysBio Managing General Partner at Frazier Healthcare
Jamie Topper, M.D., Ph.D., is a Managing General Partner of Frazier Healthcare Partner’s Life Sciences team. He joined Frazier in 2003 and opened Frazier’s Menlo Park office in the same year. Throughout his 11 years as a General Partner, Dr. Topper has invested across over 20 companies encompassing
Former President and CEO of Onyx Pharmaceuticals
Hollings Renton has previously served as the Chief Executive Officer and President of Onyx Pharmaceuticals from 1993 to 2008 and as the Chairman of the Board from 2000 to 2008. From 1991 to 1993, Mr. Renton served as President and Chief Operating Officer of Chiron Corporation, a pharmaceutical
Former CFO of Auspex Pharmaceuticals
John Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc. from September 2013 until its sale to Teva Pharmaceuticals, Inc. in June 2015. Prior to Auspex, he co-founded Trius Therapeutics, Inc., where he served as Chief Financial Officer from June 2004 until its merger with
Former Executive Vice President, Amgen
Dr. Fenton held positions of increasing responsibility at Amgen from 1982 through to his retirement in 2008, including Vice President of Research, Senior Vice President of Sales and Marketing, Senior Vice President of Operations and Executive Vice President. Previously, Dr.
Former SVP Product Development, Lilly Bio-Medicines, Eli Lilly and Company
Dr. Ware served as the Senior Vice President of Product Development of Lilly Bio-Medicines at Eli Lilly and Company, where he was responsible for the clinical development and regulatory approval of new medicines in multiple therapeutic areas. His sixteen year tenure at Eli Lilly has included the
Former Executive Vice President, Worldwide Commercial Operations, for Gilead Sciences
Laura J. Hamill joined our Board of Directors in September 2019. Ms. Hamill has extensive experience in the biopharmaceutical industry, with over 30 years of global commercial experience in a variety of executive leadership positions. She has successfully launched numerous breakthrough therapies as
President and CEO, AnaptysBio, Inc.
Hamza Suria was appointed CEO in 2011 and has since led AnaptysBio’s transformation from its early platform technology focus to the development of a robust antibody product pipeline across key therapeutic areas. Prior to AnaptysBio, Mr. Suria was at Maxygen, where he was responsible for partnering